A Pragmatic Randomized Trial of Icosapent Ethyl for High-Cardiovascular Risk Adults (NCT04505098) | Clinical Trial Compass
TerminatedPhase 4
A Pragmatic Randomized Trial of Icosapent Ethyl for High-Cardiovascular Risk Adults
Stopped: The study was suspended by the IRB of record and subsequently terminated
United States39,600 participantsStarted 2020-08-07
Plain-language summary
MITIGATE is a prospective, open-label, parallel-group, randomized, pragmatic clinical trial. The MITIGATE Study has been designed to evaluate the real-world clinical effectiveness of pre-treatment with icosapent ethyl (IPE), also known as Vascepa®, compared to usual standard of care to prevent and reduce the sequelae of laboratory-confirmed viral upper respiratory infection (URI)-related (i.e., COVID-19, influenza, and other known viral respiratory pathogens) morbidity and mortality in a high-risk cohort of adults with established atherosclerotic cardiovascular disease (ASCVD).
Who can participate
Age range50 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Able to provide informed consent (for the intervention arm only)
* No prior history of confirmed COVID-19 (i.e., based on a positive FDA-approved assay for SARS-CoV-2 and no documented FDA-approved serological test results for antibodies to SARS-CoV-2 found in health system databases)
* Established ASCVD (i.e., defined as prior myocardial infarction, percutaneous coronary intervention, coronary artery bypass surgery, ischemic stroke, and/or peripheral artery disease)
* At least 12 months of continuous health plan membership and prescription drug benefit prior to enrollment
* A registered e-mail address with the health care delivery system in order to facilitate obtaining electronic consent for study participation
Exclusion Criteria:
* Receipt of IPE on or within 12 months before the day of enrollment
* Known hypersensitivity to IPE, fish, and/or shellfish
* Documented use of any omega-3 fatty acid medications or dietary supplements containing omega-3 fatty acids in the EHR
* Women who are pregnant or planning to become pregnant
* Hospitalization for myocardial infarction and/or elective percutaneous coronary intervention within the past 1 month
* Currently receiving triple anti-thrombotic therapy
* Stage D heart failure
* Severe liver disease
* End-stage renal disease requiring chronic dialysis or estimated glomerular filtration rate \<15 mL/min/1.73 m2
* Metastatic cancer and/or receiving active systemic chemotherapy
* Institutionalized and/or receiv…